TICKERNOMICS Sign up
Last Update: 2023-12-23 05:59:09
PROTHENA CORP PUBLIC LTD CO ( PRTA ) https://www.prothena.com
37.27USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
Ireland
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-35.54%
PRTA
SPY
30.72%
PRTA
181.28%
SPY
112.82%
PRTA
326.92%
SPY
201.04%
PRTA
35.58%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
2161.81
1501.65
0.47
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-29.53
15.33
3.50
-2.67
0.00
-13.53
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
12.15
100.00
-78.73
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
6.2198
-12.72
-15.92
0.57
Other Earnings and Cash Flow Stats:
PROTHENA CORP PUBLIC LTD CO ( PRTA ) Net Income TTM ($MM) is -64.37
PROTHENA CORP PUBLIC LTD CO ( PRTA ) Operating Income TTM ($MM) is -96.42
PROTHENA CORP PUBLIC LTD CO ( PRTA ) Owners' Earnings Annual ($MM) is 0.00
PROTHENA CORP PUBLIC LTD CO ( PRTA ) Current Price to Owners' Earnings ratio is 0.00
PROTHENA CORP PUBLIC LTD CO ( PRTA ) EBITDA TTM ($MM) is -93.33
PROTHENA CORP PUBLIC LTD CO ( PRTA ) EBITDA Margin is -78.73%
Capital Allocation:
PROTHENA CORP PUBLIC LTD CO ( PRTA ) has paid 0.00 dividends per share and bought back -11.018 million shares in the past 12 months
PROTHENA CORP PUBLIC LTD CO ( PRTA ) has increased its debt by 2.701 million USD in the last 12 months
Capital Structure:
PROTHENA CORP PUBLIC LTD CO ( PRTA ) Interest-bearing Debt ($MM) as of last quarter is 10
PROTHENA CORP PUBLIC LTD CO ( PRTA ) Annual Working Capital Investments ($MM) are -700
PROTHENA CORP PUBLIC LTD CO ( PRTA ) Book Value ($MM) as of last quarter is 617
PROTHENA CORP PUBLIC LTD CO ( PRTA ) Debt/Capital as of last quarter is 1%
Other Balance Sheet Stats:
PROTHENA CORP PUBLIC LTD CO ( PRTA ) has 670 million in cash on hand as of last quarter
PROTHENA CORP PUBLIC LTD CO ( PRTA ) has 53 million of liabilities due within 12 months, and long term debt 0 as of last quarter
PROTHENA CORP PUBLIC LTD CO ( PRTA ) has 58 common shares outstanding as of last quarter
PROTHENA CORP PUBLIC LTD CO ( PRTA ) has 0 million USD of preferred stock value
Academic Scores:
PROTHENA CORP PUBLIC LTD CO ( PRTA ) Altman Z-Score is 9.01 as of last quarter
PROTHENA CORP PUBLIC LTD CO ( PRTA ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
PROTHENA CORP PUBLIC LTD CO ( PRTA ) largest shareholder is owning shares at 0.00 ($MM) value
Karin L. Walker(an insider) Sold 5000 shares of PROTHENA CORP PUBLIC LTD CO ( PRTA ) for the amount of $170000.00 on 2023-11-30
4.71% of PROTHENA CORP PUBLIC LTD CO ( PRTA ) is held by insiders, and 99.21% is held by institutions
PROTHENA CORP PUBLIC LTD CO ( PRTA ) went public on 2012-12-21
Other PROTHENA CORP PUBLIC LTD CO ( PRTA ) financial metrics:
FCF:-74.75
Unlevered Free Cash Flow:0.00
EPS:1.51
Operating Margin:12.15
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:14.20
Beta:0.57
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About PROTHENA CORP PUBLIC LTD CO ( PRTA ) :
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer's disease and other neurodegenerative diseases. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.